Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus BUTISOL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus BUTISOL SODIUM.
BUTALAN vs BUTISOL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
Oral: 50-100 mg 3-4 times daily; maximum 600 mg daily.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 40-70 hours (mean 60 h) in adults; prolonged in elderly, hepatic impairment, and neonates (up to 100 h). Clinical context: Accumulation occurs with repeated dosing.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Primarily hepatic metabolism (80%) with renal excretion of inactive metabolites (<30% unchanged). Less than 1% excreted in feces.
Category C
Category C
Barbiturate
Barbiturate